During a webcast, experts discussed the current and future treatment landscape of hepatocellular carcinoma and the need to explore combinations with chemotherapy.
Jordyn Sava
Jordyn Sava is an editor for Targeted Oncology.
Articles by Jordyn Sava
Preclinical data of soquelitinib has demonstrated tumor responses in difficult to treat T-cell malignancies. The agent will now be evaluated in a phase 3 study in relapsed peripheral T cell lymphoma.
Patients with heavily pretreated head and neck cancer achieved an overall response rate of 24% with enfortumab vedotin in the phase 2 EV-202 study.
According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.
According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.
In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.
Data points to the loss of predictive value of an interim PET2 scan for patients with Hodgkin lymphoma when treated with a regimen containing brentuximab vedotin.
The Independent Data Safety Monitoring Committee for the phase 2 ASCEND trial has given the okay to continue evaluation of LSTA1 for patients with pancreatic cancer.
Guidance from the FDA has provided a clear pathway and requested no additional efficacy or safety trials for the resubmission of the biologics license application for denileukin diftitox in cutaneous T-cell lymphoma.
The median progression-free survival rates were 19.3 months with brigatinib and 19.2 months with alectinib in the phase 3 ALTA-3 study for patients with ALK-positive non–small cell lung cancer.
INT230-6 is an investigational product candidate made up of cisplatin, vinblastine, and a penetration enhancer molecule being evaluated for patients with soft tissue sarcoma.
If approved, DB-1303 may provide a potential alternative to treatment with fam-trastuzumab deruxtecan-nxki for the treatment of patients with breast cancer.
With the emergence of tyrosine kinase inhibitors and targeted immunotherapies in the front line, outcomes for patients with ALL have improved. However, questions about central nervous system involvement and prophylaxis persist.
Targeted Oncology recently honored 3 outstanding oncologists who have been influential in the community oncology space for years.
In an interview with Targeted Oncology, Binod Dhakal, MD, discussed results from the phase 3 CARTITUDE-4 study of cilta-cel in patients with lenalidomide-refractory multiple myeloma.
In an interview with Targeted Oncology, Nirav Shah, MD, discussed long-term follow-up results from the phase 1/2 BRUIN study and how the approval of pirtobrutinib has changed the MCL treatment landscape.
As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.
Regardless of mismatch repair status, the phase 3 NRG-GY018 trial showed an improvement in progression-free survival when patients with endometrial cancer were given pembrolizumab with chemotherapy.
Alectinib is the first and only ALK inhibitor to demonstrate a reduction in disease recurrence among patients with early-stage ALK-positive non–small cell lung cancer, based on data from the phase 3 ALINA study.
In an interview with Targeted Oncology, Ruchi Garg, MD, discussed the evolution of the treatment landscape for patients with endometrial cancer and what trials to watch out for in the future.
Following positive results from cohorts 1 and 2 of the SECuRE trial, dosing of 64Cu/67Cu SAR-bisPSMA has begun in patients with metastatic castration-resistant prostate cancer in cohort 3.
In an interview Targeted Oncology, Christina Fotopoulou, MD, PhD, discussed the background and results of 3 studies for patients with ovarian cancer.
Amid the ongoing chemotherapy drug shortage in the United States, experts like Nathan Bahary, MD, and Anne LaCasce, MD, MMSc, push for the passing of legislation, yet keep their patients their top priority.
The phase 1/2 BEXMAB study is investigating the combination of bexmarilimab with standard of care in patients with hematologic malignancies.
Promising overall survival findings from cohort 1 of the THOR study evaluating erdafitinib in locally advanced or metastatic urothelial cancer have pushed the agent’s developer to submit an sNDA seeking its full approval.
Study results suggest that patients with myelodysplastic syndrome have the potential to benefit from HCT regardless of their genetic mutations.
The FDA has added to the existing approval of luspatercept-aamt for the treatment of patients with anemia and lower-risk myelodysplatic syndrome.
Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.
The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.
In an interview with Targeted Oncology, Daniel P. Petrylak, MD, discussed findings from the TROPHY-U-01 study for patients with mUC, and what the next steps for research are.